Asuka Pharmaceutical Holdings Inc.

Founder Yamaguchi Hachijūhachi opened the import business 'Yamaguchi Hachijūhachi Shōten' for foreign liquors and food products.

Founder Yamaguchi Hachijūhachi opened the import business 'Yamaguchi Hachijūhachi Shōten' for foreign liquors and food products.

Established the 'Teikoku-sha Food Division Factory' in Yokohama, producing and selling Japan's first artificial butter (margarine).

Established the 'Teikoku-sha Food Division Factory' in Yokohama, producing and selling Japan's first artificial butter (margarine).

The company established its founding date as June 16, 1920, the day it began manufacturing the male hormone drug 'Spelmin'.

Founded the Teikoku-sha Organ Drug Research Institute based on the idea of creating useful medicines from animal organs, and began manufacturing the male hormone drug 'Spelmin'. This was deemed the founding of the company.

Established the company on June 16, 1920, by founding the Teikoku-sha Organ Drug Research Institute within the Teikoku-sha Food Division Factory and beginning production of the male hormone drug 'Spelmin'.

Founded the Teikoku-sha Organ Drug Research Institute within the Teikoku-sha Food Division Factory and began manufacturing the male hormone drug 'Spelmin', which was deemed the founding date of the company.

Changed to a stock corporation and was named 'Teikoku-sha Organ Drug Research Institute Inc.'.

Established a new Takatsu factory (Kawasaki Research Institute) in Takatsu-cho, Tachikawa-gun, Kanagawa Prefecture (now Takatsu-ku, Kawasaki City).

Moved headquarters to Kawaguchi, Kawasaki City (within Takatsu factory premises) and renamed the company to Teikoku Organ Pharmaceutical Co., Ltd.

Moved headquarters to Sakuma-cho, Shiba-nan, Minato-ku, Tokyo.

Established a branch office in Osaka.

Listed shares on the Tokyo Stock Exchange.

Established a branch office in Fukuoka.

Established a branch office in Nagoya.

Established a branch office in Sapporo.

Established a sales office in Tokyo.

Moved headquarters to 2-5-1 Akasaka, Minato-ku, Tokyo.

Established branch offices in Sendai and Hiroshima.

Completed a new research building on the Kawasaki Research Institute site.

Established a branch office in Yokohama.

Established a new Iwaki factory.

Established a sales office in Kyoto.

Established Medical System Service Kanagawa Inc. (now Asuka Pharmaceutical Medical Inc.) as a consolidated subsidiary.

Reclassified to the First Section of the Tokyo Stock Exchange.

Established an international expatriate office in Frankfurt.

Moved headquarters to 2-5-1 Shibaura, Minato-ku, Tokyo.

Approved a merger agreement with Grelan Pharmaceutical Co., Ltd.

Merged with Grelan Pharmaceutical Co., Ltd. and changed the company name to Asuka Pharmaceutical Co., Ltd.

Established by renaming and merging from Medical System Service Kanagawa Inc.

Renamed and merged from Medical System Service Kanagawa Inc., establishing Asuka Pharmaceutical Medical Inc.

Established Asuka Actavis Pharmaceutical Co., Ltd.

Established a separate company for the animal health business of Asuka Pharmaceutical (formerly Teikoku Organ Pharmaceutical).

Separated the animal health business of Asuka Pharmaceutical (formerly Teikoku Organ Pharmaceutical) and established Asuka Animal Health Co., Ltd.

Established Asuka Animal Health Co., Ltd. (consolidated subsidiary).

Absorbed and merged Asuka Actavis Pharmaceutical Co., Ltd.

Jointly invested in NeoASKA Pharma Private Limited in India with Omnicare Drugs India Private Limited.

Established the 'Health Lab Mint+' for women as part of social contribution activities on the company's 100th anniversary.

Moved to the Shonan Health Innovation Park in Fujisawa City, Kanagawa Prefecture, specializing in testing services.

Established the 'Health Lab Mint+' for women to commemorate the 100th anniversary of Asuka Pharmaceutical.

Moved Kawasaki Research Institute (Kawasaki City, Kanagawa Prefecture) to Shonan Research Institute (Fujisawa City, Kanagawa Prefecture).

Invested in Ha Tay Pharmaceutical Joint Stock Company in Vietnam (equity method affiliate).

Asuka Pharmaceutical Co., Ltd. established this company through a standalone share transfer, and its shares were listed on the First Section of the Tokyo Stock Exchange (Asuka Pharmaceutical Co., Ltd. was delisted in March 2021). Additionally, it acquired all shares of Asuka Animal Health Co., Ltd. and Asuka Pharmaceutical Medical Inc. held by Asuka Pharmaceutical Co., Ltd. through a stock dividend, making them direct subsidiaries.

Invested in Nihon Glass Industry Co., Ltd. (equity method affiliate).

Established a London office.

Asuka Pharmaceutical Co., Ltd. established this company through a standalone share transfer, and its shares were listed on the First Section of the Tokyo Stock Exchange (Asuka Pharmaceutical Co., Ltd. was delisted in March 2021).

Acquired all shares of Asuka Animal Health Co., Ltd. and Asuka Pharmaceutical Medical Inc. held by Asuka Pharmaceutical Co., Ltd. through a stock dividend, making them direct subsidiaries.

The birth of Asuka Pharmaceutical Holdings Inc.

Moved from the First Section to the Prime Market of the Tokyo Stock Exchange due to a review of market classifications.

Made Ha Tay Pharmaceutical Joint Stock Company a consolidated subsidiary.